Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.

Inclusion Criteria:Nulliparous women aged 18 years or morePregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donorSingleton pregnancyEvolutive pregnancy between 9 and 14 weeks of gestationWomen affiliated to a French Social Security Insurance or equivalent social protectionWritten informed consentExclusion Criteria:Major fetal abnormalityRegular treatment with aspirin (including antiphospholipid syndrome)Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia)Women protected by law.Women included in another interventional study.